Bayer Looks To Turn Aleve Around Following Negative Media Hit
This article was originally published in The Tan Sheet
Executive Summary
Press coverage of a halted NIH study that called into question the cardiovascular safety of naproxen will cause an approximate $30 mil. decline in first-quarter U.S. Aleve sales, according to Bayer
You may also be interested in...
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
Aleve Campaign Cites Media Reports Of FDA Advisory Panel Opinions
A new ad campaign for Bayer's Aleve touts FDA advisory committee commentary regarding the safety of naproxen in relation to other analgesics
Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says
Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18